Roche and GSK Collaborationin December 2001 announced by F. Hoffmann – La Roche and GlaxoSmithKline its plans to co-promote Boniva for the treatment and prevention of postmenopausal osteoporosis in all countries except Japan. The Roche and GSK offers expertise and commitment to bringing new osteoporosis therapies to market as quickly as possible.
Together, osteoporosis and osteopenia it is expected that an estimated 52 million men and women aged 50 and older by 2013, affect 61 million by 2020.2 Direct medical costs of osteoporosis total nearly 18 billion in the U.S. Each year.1.Unexpectedly Death Receptor links cancer susceptibility and inflammationhave Since over 10 years Wafik S. El-Deiry, Professor of Medicine, genetic and Pharmacology at the University of Pennsylvania School of Medicine, pursues a cancer targeting molecule called TRAIL and to its molecular partner. Is TRAIL normally by immune cells and tumor spread curtails by binding to a receptor on a tumor created specialized surface.
Primary-care medical consisting of the University of Pennsylvania School of Medicine and University of Pennsylvania HealthSystem.. El-Deiry and his team are now looking in the tumor tissue of inflammatory molecules as indication of how cancer and inflammation associated. Our work with TRAIL and whose receptor in mouse models a new way learn at looking reduced cancer susceptibility and their potential Treatment In Humans and new approaches to debilitating rays adverse effects from cancer patients is, says El-Deiry.
PENN Medicine & Health is a $ 3500000000 company that has to tasks associated with in medical education, biomedical research, and excellence of patient care.